The Centers for Medicare and Medicaid Services (CMS) on Wednesday issued a sweeping final rule for the 2027 Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center (ASC) payment system, signaling a fundamental shift in how the federal government reimburses hospitals and clinics. The regulation introduces aggressive cuts to the 340B drug discount program, expands the scope of site-neutral payment policies to include a wide array of imaging services, and continues the phased elimination of the inpatient-only procedure list. While CMS framed the changes as a necessary move toward fiscal sustainability and lower out-of-pocket costs for seniors, the hospital industry has reacted with sharp criticism, warning that the "assault" on safety-net programs will jeopardize the financial stability of facilities serving the nation’s most vulnerable populations.
The 340B Reimbursement Overhaul: A Multibillion-Dollar Shift
The most contentious element of the 2027 final rule is the decision to slash reimbursement rates for drugs acquired through the 340B Federal Drug Discount Program. Under the new guidelines, Medicare will reimburse 340B-participating hospitals at the drug’s Average Sales Price (ASP) minus 28%. This represents a significant departure from the standard Medicare Part B reimbursement rate, which typically pays the ASP plus 6% to cover administrative costs and overhead.
Regulators estimate that this policy shift will reduce federal drug spending by approximately $5.5 billion in the next calendar year alone. The 340B program, established in 1992, was originally intended to allow safety-net hospitals to stretch scarce federal resources by purchasing outpatient drugs at a discount and using the savings to provide care for uninsured and low-income patients. However, the program has faced increasing scrutiny from the Trump administration and some members of Congress, who argue that the program has "ballooned out of control," reaching over $100 billion in total drug purchases in recent years.
The CMS rationale for the cut is rooted in the belief that hospitals should not profit excessively from the spread between the discounted purchase price of 340B drugs and the higher Medicare reimbursement rate. By aligning payments more closely with the actual acquisition costs, officials argue that the savings can be passed on to beneficiaries in the form of lower co-pays.
However, because Medicare rules require such changes to be budget-neutral, the $5.5 billion saved from drug payments will be redistributed into the broader OPPS pool. This redistribution will result in a corresponding increase in reimbursement rates for non-drug services. This specific mechanism creates a "winners and losers" scenario: for-profit hospital systems, which generally do not participate in the 340B program, are expected to see a significant financial tailwind from the increased non-drug payment rates, while nonprofit safety-net hospitals face a net loss in revenue.
Expansion of Site-Neutral Payment Policies
Building on a multi-year effort to equalize payments across different healthcare settings, the 2027 final rule broadens site-neutral policies to include imaging services provided without contrast. Starting next year, Medicare will pay the same rate for CT scans, MRIs, X-rays, and bone density scans, regardless of whether they are performed in a hospital-owned outpatient department (HOPD) or a freestanding physician’s office or imaging center.
Historically, Medicare has paid significantly higher rates to hospital-owned facilities for the same services provided in independent clinics. CMS and various policy experts have long argued that these payment disparities incentivize hospitals to acquire independent physician practices, leading to market consolidation that drives up healthcare costs without necessarily improving quality.
The expansion to imaging services is expected to save taxpayers and Medicare beneficiaries more than $9 billion over the next decade. By eliminating the financial incentive for hospitals to charge "facility fees" for basic diagnostic imaging, the administration aims to lower the out-of-pocket burden on seniors, many of whom face 20% coinsurance for these services.
"By right-sizing payments and rooting out waste, today’s reforms will drive affordability in Medicare for current beneficiaries while ensuring it will still be there to serve their children and grandchildren," said CMS Administrator Dr. Mehmet Oz in an official statement. This move reinforces the administration’s stance that a "service is a service," and the location of that service should not dictate a vastly different price tag for the federal government.
Phasing Out the Inpatient-Only List
In a move that continues to blur the lines between inpatient and outpatient care, CMS has finalized the removal of 637 services from the "inpatient-only" (IPO) list. This list historically designated procedures that Medicare would only reimburse if performed in a hospital inpatient setting due to their complexity or the need for postoperative monitoring.
The 2027 removals include a wide range of endocrine, digestive, auditory, and respiratory procedures. This marks the second consecutive year that the agency has significantly reduced the IPO list, with a stated goal of phasing the list out entirely over the next three years. Regulators argue that advancements in surgical techniques, anesthesia, and post-operative care have made it safe and often preferable for these procedures to be performed in outpatient departments or Ambulatory Surgery Centers (ASCs).
By moving these procedures to the outpatient setting, CMS expects to realize substantial savings, as outpatient facility fees are generally lower than inpatient stays. For patients, this shift often translates to faster recovery times and lower costs, though hospital groups have raised concerns about whether certain high-risk patients may still require the intensive resources of an inpatient setting that may no longer be adequately reimbursed.
Payment Updates and Economic Context
For the 2027 calendar year, CMS has set the payment update for hospital outpatient departments and ASCs at 2.3%. This figure is a slight downward adjustment from the 2.4% increase that was initially proposed in July. The 2.3% update is based on a projected hospital market basket increase of 3.0%, which is then reduced by a 0.7 percentage point productivity adjustment required by law.
The American Hospital Association (AHA) and other industry advocates have labeled this update as "woefully inadequate." They point to the persistent inflationary pressures on labor, supplies, and pharmaceuticals that have squeezed hospital margins since the pandemic. According to the AHA, a 2.3% increase fails to keep pace with the actual cost of providing care in the current economic environment.
Industry Reaction and Political Backlash
The hospital industry’s response to the final rule has been one of uniform opposition. Ashley Thompson, the AHA’s senior vice president of public policy analysis and development, issued a scathing statement following the release of the rule.
"The continued assault on the 340B program is deeply disturbing and will put further stress on hospitals that are already operating on razor-thin margins," Thompson stated. She further argued that the expansion of site-neutral payments ignores the higher "mission-driven" costs that hospitals incur, such as maintaining 24/7 emergency departments, providing uncompensated care, and adhering to more stringent regulatory and safety standards than freestanding clinics.
Legal experts anticipate that the cuts to the 340B program may trigger a new round of litigation. The program has been the subject of several high-profile court battles over the last decade, including a 2022 Supreme Court ruling that previously struck down CMS’s authority to cut 340B rates without conducting a formal survey of hospital acquisition costs. By framing these new cuts within the context of updated data and broader administrative goals, CMS is attempting to navigate those legal hurdles, though the hospital lobby remains poised to challenge the validity of the ASP minus 28% formula.
Chronology of Recent Regulatory Actions
The 2027 final rule represents the culmination of a decade-long trajectory in Medicare policy:
- 2018-2019: The Trump administration first introduced significant cuts to 340B payments and began the initial "site-neutral" push for clinic visits (HCPCS code G0463).
- 2022: The Supreme Court ruled in AHA v. Becerra that the 340B cuts implemented in previous years were unlawful because CMS had not properly surveyed hospital costs.
- 2024-2025: CMS implemented "remedy" payments to compensate hospitals for the previous unlawful cuts but simultaneously began signaling a return to a lower reimbursement model for 340B drugs based on new data sets.
- 2026: Regulators proposed the current 2027 framework, including the expansion of site-neutral imaging and the aggressive 340B reduction.
- November 2026: The final rule is released, cementing the ASP minus 28% rate and the removal of hundreds of procedures from the IPO list.
Implications for the Healthcare Landscape
The long-term implications of the 2027 OPPS final rule are likely to be profound. For patients, the reduction in 340B drug costs and the equalization of imaging fees should lead to tangible savings at the point of care. For the federal government, the rule represents a major step toward curbing the growth of Medicare Part B spending.
However, for the healthcare delivery system, the rule may accelerate several existing trends. First, the financial pressure on 340B hospitals may lead some safety-net providers to scale back specialized outpatient services or reduce community outreach programs funded by 340B savings. Second, the for-profit sector may see an increase in stock valuations as the budget-neutral redistribution of funds favors systems with low 340B participation. Finally, the elimination of the inpatient-only list will likely fuel the continued growth of the ASC market, as surgeons move high-volume procedures out of the traditional hospital setting.
As the healthcare industry prepares for the implementation of these changes on January 1, 2027, the focus will likely shift to Capitol Hill, where hospital lobbyists are expected to press for legislative interventions to mitigate the impact of the 340B cuts and the site-neutral expansions. For now, CMS has made its position clear: the era of higher payments for hospital-based outpatient services is drawing to a close in favor of a more standardized, cost-conscious Medicare program.
